公开(公告)号：US12123046B2

公开(公告)日：2024-10-22

申请号：US16979161

申请日：2019-03-08

申请人： ULTIZYME INTERNATIONAL LTD. ,  I-SENS, INC.

发明人： Koji Sode ,  Youngjea Kang ,  Kazushige Mori ,  Katsuhiro Kojima ,  Junko Shimazaki

IPC分类号： C12Q1/00 ,  C07K14/80 ,  C12N9/04 ,  C12N15/62 ,  C12Q1/32

CPC分类号： C12Q1/006 ,  C07K14/80 ,  C12N9/0006 ,  C12N15/62 ,  C12Q1/32 ,  C07K2319/00 ,  C12Y101/05

摘要： The purpose of the present invention is to provide a fungus-derived FADGDH that has a direct electron transfer ability. Provided is a fusion protein comprising a fungus-derived FADGDH or a mutant thereof and a cytochrome molecule connected to the N-terminus of the FADGDH or variant thereof.

公开(公告)号：US12122995B2

公开(公告)日：2024-10-22

申请号：US16726163

申请日：2019-12-23

申请人： DNA2.0, INC.

发明人： Jeremy Minshull ,  Mark Welch ,  Sridhar Govindrajan ,  Maggie Lee ,  Kate Caves ,  Jon Ness

IPC分类号： C12N9/12 ,  C12N1/16 ,  C12N1/18 ,  C12N15/10 ,  C12N15/52 ,  C12N15/62 ,  C12N15/63 ,  C12N15/67 ,  C12N15/81 ,  C12N15/85 ,  C12N15/90 ,  C12R1/84 ,  C12R1/865

CPC分类号： C12N1/165 ,  C12N1/185 ,  C12N9/12 ,  C12N9/1241 ,  C12N15/1082 ,  C12N15/52 ,  C12N15/625 ,  C12N15/63 ,  C12N15/81 ,  C12N15/815 ,  C12N15/85 ,  C12N15/8509 ,  C12N15/90 ,  C12Y207/00 ,  C12Y207/07 ,  C07K2319/09 ,  C12N15/67 ,  C12N2800/90 ,  C12N2830/007 ,  C12N2830/40 ,  C12N2830/42 ,  C12N2840/203 ,  C12R2001/84 ,  C12R2001/865

摘要： The present invention provides polynucleotide vectors for high expression of heterologous genes. Some vectors further comprise novel transposons and transposases that further improve expression. Further disclosed are vectors that can be used in a gene transfer system for stably introducing nucleic acids into the DNA of a cell. The gene transfer systems can be used in methods, for example, gene expression, bioprocessing, gene therapy, insertional mutagenesis, or gene discovery.

公开(公告)号：US12121578B2

公开(公告)日：2024-10-22

申请号：US17431833

申请日：2020-02-27

申请人： KM Biologics Co., Ltd.

发明人： Ryo Yamaue ,  Satoshi Kamakura ,  Mihoko Matsuo ,  Masaharu Torikai ,  Hiroaki Mori

IPC分类号： A61K39/155 ,  A61P31/14 ,  C12N7/00 ,  C12N15/62

CPC分类号： A61K39/155 ,  A61P31/14 ,  C12N7/00 ,  C12N15/62

摘要： A novel vaccine antigen for prevention of Respiratory Syncytial Virus (RSV) infection is created which surpasses conventional vaccines comprising as an antigen RSV F protein alone in view of efficacy and/or safety. A vaccine is prepared which comprises as an antigen a RSV F/G chimeric protein wherein a portion of RSV F protein as a basic structure is replaced with a whole or a portion of Conserved Central Domain sequence of RSV G protein or wherein a whole or a portion of Conserved Central Domain sequence of RSV G is added to the basic structure. As a result of assessment of both efficacy and safety, a vaccine comprising as an antigen the F/G chimeric protein of the present invention confirmed to be more excellent than a vaccine comprising as an antigen RSV F protein alone in view of efficacy and/or safety.

公开(公告)号：US20240343801A1

公开(公告)日：2024-10-17

申请号：US18442779

申请日：2024-02-15

申请人： APTEVO RESEARCH AND DEVELOPMENT LLC

发明人： Gabriela HERNANDEZ-HOYOS ,  Elaine T. SEWELL ,  Catherine J. MCMAHAN ,  David BIENVENUE ,  John W. BLANKENSHIP ,  Danielle MITCHELL ,  Peter PAVLIK

IPC分类号： C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  A61P35/02 ,  C07K16/00 ,  C07K16/30 ,  C12N15/62

CPC分类号： C07K16/2809 ,  A61P35/00 ,  A61P35/02 ,  C07K16/2866 ,  C07K16/2896 ,  C07K16/3061 ,  C12N15/62 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/005 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/75 ,  C07K2317/90 ,  C07K2317/92 ,  C07K2317/94

摘要： The present disclosure relates to protein molecules that specifically bind to CD123, which may have at least one humanized or human CD123-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to CD123 may have a second binding domain that binds to another target. In one embodiment, multi-specific polypeptide molecules bind both CD123-expressing cells and the T-cell receptor complex on T-cells to induce target-dependent T-cell cytotoxicity, activation, and proliferation. The disclosure also provides pharmaceutical compositions comprising the CD123-binding polypeptide molecules, nucleic acid molecules encoding these polypeptides and methods of making these molecules.

公开(公告)号：US12116609B2

公开(公告)日：2024-10-15

申请号：US17159850

申请日：2021-01-27

申请人： Wisconsin Alumni Research Foundation

发明人： Brian Frederick Pfleger ,  Jacqueline Marie Rand ,  Christopher Robert Mehrer ,  Matthew Ryan Incha

IPC分类号： C12P7/04 ,  C12N9/10 ,  C12N9/18 ,  C12N15/52 ,  C12N15/62 ,  C12N15/63 ,  C12N15/64 ,  C12N15/66 ,  C12N15/69 ,  C12P7/16 ,  C12P7/26

CPC分类号： C12P7/16 ,  C12N9/1029 ,  C12N9/18 ,  C12N15/52 ,  C12N15/62 ,  C12N15/63 ,  C12N15/64 ,  C12N15/66 ,  C12N15/69 ,  C12P7/26 ,  C12Y203/01009 ,  C12Y208/03 ,  C12Y301/01

摘要： Described is a recombinant expression vector that enables a cell transformed to contain and express the vector to use levulinic acid as a carbon source, thereby converting levulnic acid into 2-butanne. Also described are genetically modified cells transformed to contain and express the vector and methods of using the cells to produce 2-butanone from a medium containing levulinic acid.

公开(公告)号：US20240309083A1

公开(公告)日：2024-09-19

申请号：US18737713

申请日：2024-06-07

申请人： Sonnet BioTherapeutics, Inc.

发明人： John K. Cini ,  Haomin Huang

IPC分类号： C07K16/24 ,  A61K38/00 ,  A61K39/00 ,  A61K39/395 ,  A61P35/00 ,  C07K14/715 ,  C07K14/76 ,  C07K16/18 ,  C07K16/22 ,  C07K16/28 ,  C07K16/46 ,  C12N15/62 ,  C12N15/63

CPC分类号： C07K16/244 ,  A61K39/001138 ,  A61K39/00114 ,  A61K39/3955 ,  A61P35/00 ,  C07K14/7155 ,  C07K16/18 ,  C07K16/22 ,  C07K16/2818 ,  C07K16/468 ,  A61K38/00 ,  A61K2039/6081 ,  C07K14/76 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2319/00 ,  C12N15/62 ,  C12N15/63 ,  C12N2510/00 ,  C12N2800/00

摘要： Compositions that include an albumin binding domain and a fusion partner (e.g., a cytokine or a binding moiety) are provided. Such therapeutics have increased serum half-life and find use in applications where one or more such therapeutics are needed, for example, in oncology applications.

公开(公告)号：US12090193B2

公开(公告)日：2024-09-17

申请号：US18457482

申请日：2023-08-29

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Yang Wei ,  Haruka Okamoto ,  Jesper Gromada ,  Samuel Davis ,  Andrew J. Murphy

IPC分类号： A61K38/26 ,  A61K31/155 ,  A61K31/5415 ,  A61K38/00 ,  A61P3/04 ,  A61P3/10 ,  C07K14/605 ,  C07K16/08 ,  C07K16/28 ,  C12N15/62

CPC分类号： A61K38/26 ,  A61K31/155 ,  A61K31/5415 ,  A61P3/04 ,  A61P3/10 ,  C07K14/605 ,  C07K16/082 ,  C07K16/2869 ,  C12N15/62 ,  A61K38/00 ,  C07K2319/00

摘要： The present invention provides modified glucagon-like peptide 1 (GLP1) polypeptides, fusion proteins comprising modified GLP1 polypeptides, and methods of use thereof. In various embodiments of the invention, the fusion proteins are GLP1 receptor agonists that comprise a modified GLP1 fused to a stabilizing domain. In some embodiments, the fusion proteins comprising modified GLP1 are useful for treating or ameliorating a symptom or indication of a disorder such as obesity and diabetes.

公开(公告)号：US20240301432A1

公开(公告)日：2024-09-12

申请号：US17797560

申请日：2021-02-05

申请人： XBRANE BIOPHARMA AB ,  CLONEOPT AB

发明人： Kiavash MIRZADEH ,  Daniel DALEY ,  Patrick SHILLING

IPC分类号： C12N15/62 ,  C12N15/67 ,  C12N15/70 ,  C12P21/02

CPC分类号： C12N15/625 ,  C12N15/67 ,  C12N15/70 ,  C12P21/02 ,  C07K2319/02

摘要： The present invention provides a simple and inexpensive system for regulating signal peptide performance by using a synthetically evolved nucleotide sequence. The invention further relates to an expression vector comprising the nucleotide sequence. Additionally, the present invention relates to host cell comprising the expression vector. Furthermore, the present invention relates to a recombinant protein expressed by the host cell as well as a method for expressing the recombinant protein.

公开(公告)号：US20240301063A1

公开(公告)日：2024-09-12

申请号：US18671707

申请日：2024-05-22

申请人： Shandong New Time Pharmaceutical Co., Ltd.

发明人： Qiang Li ,  Shixiang Jia ,  Lili Zhao ,  Guimin Zhang ,  Zhong Liu ,  Xinlu Ma ,  Yuan Yan ,  Zhenyu Li ,  Xingxia Hu ,  Yuhua Zhang ,  Bin Li

IPC分类号： C07K16/28 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C07K16/30 ,  C07K16/32 ,  C07K16/46 ,  C12N15/62 ,  C12N15/85

CPC分类号： C07K16/2809 ,  A61K39/3955 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2803 ,  C07K16/2863 ,  C07K16/2878 ,  C07K16/2887 ,  C07K16/3007 ,  C07K16/303 ,  C07K16/32 ,  C07K16/468 ,  C12N15/62 ,  C12N15/85 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/35 ,  C07K2317/52 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/626 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2317/94

摘要： The invention provided herein relates to methods and uses of a bispecific antibody, which specifically binds the surface antigen CD3 of immune cells and the BCMA antigen on the surface of tumor cells and which may bind to human CD3 with high affinity, induce T cell proliferation, and mediate tumor cell killing effects. The bispecific antibody may be used to mediate the T cell-specific killing of target cells in in vitro tests.

公开(公告)号：US12077771B2

公开(公告)日：2024-09-03

申请号：US18327373

申请日：2023-06-01

申请人： ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY

发明人： Samira Kiani ,  Mo Reza Ebrahimkhani ,  Jennifer Chapman

IPC分类号： C12N15/85 ,  C12N9/22 ,  C12N15/11 ,  C12N15/115 ,  C12N15/62 ,  C12N15/90

CPC分类号： C12N15/85 ,  C12N9/22 ,  C12N15/11 ,  C12N15/115 ,  C12N15/62 ,  C12N15/907 ,  C12N2310/128 ,  C12N2310/16 ,  C12N2310/20 ,  C12N2501/12 ,  C12N2501/405 ,  C12N2800/80

摘要： Aspects of the disclosure relate to methods and synthetic regulatory systems for more efficient nuclease-mediated homology-directed repair (HDR). In particular, provided herein are methods for more efficient in vivo and in vitro HDR-based gene editing where the methods comprise introducing into a cell a synthetic regulatory system comprising Cas nuclease, guide RNAs (gRNAs) having various lengths and configured to target distinct nucleotide sequences for simultaneous transcriptional repression (or activation) and genome editing via double stranded break and use of a donor nucleic acid molecule as a template for repair.